tetano
Editor, Senior Moderator
Brain Behav
. 2022 Oct 28;e2789.
doi: 10.1002/brb3.2789. Online ahead of print.
COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2
Syed Muhammad Ismail Shah[SUP] 1 [/SUP], Farah Yasmin[SUP] 2 [/SUP], Roha Saeed Memon[SUP] 2 [/SUP], Nadia Nazir Jatoi[SUP] 2 [/SUP], Ilma Saleh Savul[SUP] 3 [/SUP], Sana Kazmi[SUP] 2 [/SUP], Syed Abdullah Monawwer[SUP] 1 [/SUP], Muhammad Daim Bin Zafar[SUP] 2 [/SUP], Muhammad Sohaib Asghar[SUP] 4 [/SUP], Muhammad Junaid Tahir[SUP] 5 [/SUP], Ka Yiu Lee[SUP] 6 [/SUP]
Affiliations
Abstract
Introduction: This review highlights the potential mechanisms of neuromuscular manifestation of COVID-19, especially myasthenia gravis (MG).
Methods: An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.
Results: Exacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.
Conclusions: Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.
Keywords: Guillain-Barre syndrome; immunoglobulins; infection; myasthenia gravis; pyridostigmine bromide; severe acute respiratory syndrome coronavirus 2.
. 2022 Oct 28;e2789.
doi: 10.1002/brb3.2789. Online ahead of print.
COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2
Syed Muhammad Ismail Shah[SUP] 1 [/SUP], Farah Yasmin[SUP] 2 [/SUP], Roha Saeed Memon[SUP] 2 [/SUP], Nadia Nazir Jatoi[SUP] 2 [/SUP], Ilma Saleh Savul[SUP] 3 [/SUP], Sana Kazmi[SUP] 2 [/SUP], Syed Abdullah Monawwer[SUP] 1 [/SUP], Muhammad Daim Bin Zafar[SUP] 2 [/SUP], Muhammad Sohaib Asghar[SUP] 4 [/SUP], Muhammad Junaid Tahir[SUP] 5 [/SUP], Ka Yiu Lee[SUP] 6 [/SUP]
Affiliations
- PMID: 36306401
- DOI: 10.1002/brb3.2789
Abstract
Introduction: This review highlights the potential mechanisms of neuromuscular manifestation of COVID-19, especially myasthenia gravis (MG).
Methods: An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.
Results: Exacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.
Conclusions: Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.
Keywords: Guillain-Barre syndrome; immunoglobulins; infection; myasthenia gravis; pyridostigmine bromide; severe acute respiratory syndrome coronavirus 2.